Get the Stockscreener App
0.544
72.81%
0.2292
After Hours:
.53
-0.014
-2.57%
Immutep Limited Adr stock is traded at $0.544, with a volume of 700.12M.
It is up +72.81% in the last 24 hours and up +12.26% over the past month.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
See More
Previous Close:
$0.3148
Open:
$1.01
24h Volume:
700.12M
Relative Volume:
59.20
Market Cap:
$80.17M
Revenue:
-
Net Income/Loss:
$-54.17M
P/E Ratio:
-1.4707
EPS:
-0.3699
Net Cash Flow:
$-39.34M
1W Performance:
+54.28%
1M Performance:
+12.26%
6M Performance:
-74.34%
1Y Performance:
-63.97%
1-Day Range:
$0.5333
$1.0499
1-Week Range:
$0.2928
$1.0499
52-Week Range:
$0.2928
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
0.544 | 46.39M | 0 | -54.17M | -39.34M | -0.3699 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Downgrade | Citizens | Mkt Outperform → Mkt Perform |
| Mar-13-26 | Downgrade | Maxim Group | Buy → Hold |
| Mar-13-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-17-26 | Initiated | Citizens | Mkt Outperform |
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.15% - Investing.com
These stocks are moving in today's session - ChartMill
Which stocks are most active on Wednesday? - ChartMill
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Benzinga
Here are the top movers in Wednesday's session. - ChartMill
Dow Gains 100 Points; Bank of America Earnings Top Views - Benzinga
These stocks are moving in today's pre-market session - ChartMill
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - Barchart
Working capital per share of Immutep Ltd Sponsored ADR – FWB:YP1A - TradingView — Track All Markets
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - GlobeNewswire Inc.
IMMP Stock Price, Quote & Chart | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - ChartMill
POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GlobeNewswire Inc.
IMMP Investor News: If You Have Suffered Losses in Immutep - GlobeNewswire
Immutep (NASDAQ: IMMP) reports positive Phase I progress for LAG-3 agonist IMP761 - Stock Titan
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Immutep Limited (IMMP) And Encourages Investors to Reach Out - accessnewswire.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep LimitedIMMP - FinancialContent
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP - FinancialContent
On Tuesday, there are stocks with unusual volume. Let's take a look. - chartmill.com
IMM:ASX AnnouncementChange in substantial holding17 Mar 2026 - Market Index
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Sahm
Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early - Sahm
This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% By Investing.com - Investing.com India
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com
This EverCommerce analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
This EverCommerce Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Immutep (NASDAQ: IMMP) lands efti licensing deal and funds runway to Q2 2027 - Stock Titan
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Immutep reports positive phase I data for first-in-class autoimmune antibody IMP761 - MSN
Immutep Limited Adr Stock (IMMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):